

Marquette University

e-Publications@Marquette

Biomedical Sciences Faculty Research and
Publications

Biomedical Sciences, Department of

2-2019

Roles for the Uptake₂ Transporter OCT3 in Regulation of Dopaminergic Neurotransmission and Behavior

Paul J. Gasser

Marquette University, paul.gasser@marquette.edu

Follow this and additional works at: https://epublications.marquette.edu/biomedsci_fac



Part of the [Neurosciences Commons](#)

Recommended Citation

Gasser, Paul J., "Roles for the Uptake₂ Transporter OCT3 in Regulation of Dopaminergic Neurotransmission and Behavior" (2019). *Biomedical Sciences Faculty Research and Publications*. 191. https://epublications.marquette.edu/biomedsci_fac/191

Marquette University

e-Publications@Marquette

Biomedical Sciences Faculty Research and Publications/College of Health Sciences

This paper is NOT THE PUBLISHED VERSION; but the author's final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation below.

Neurochemistry International, Vol. 123, (February 2019): 46-49. [DOI](#). This article is © Elsevier and permission has been granted for this version to appear in [e-Publications@Marquette](#). Elsevier does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

Roles for the Uptake₂ Transporter OCT₃ in Regulation of Dopaminergic Neurotransmission and Behavior

Paul J. Gasser

Department of Biomedical Sciences, Marquette University, Milwaukee, WI

Abstract

Transporter-mediated uptake determines the peak concentration, duration, and physical spread of released [monoamines](#). Most studies of monoamine clearance focus on the presynaptic uptake₁ transporters SERT, NET and DAT. However, recent studies have demonstrated the expression of the uptake₂ transporter OCT₃ (organic cation transporter 3), throughout the rodent brain. In contrast to NET, DAT and SERT, OCT₃ has higher capacity and lower affinity for substrates, is sodium-independent, and is multi-specific, with the capacity to transport [norepinephrine](#), dopamine, [serotonin](#) and [histamine](#). OCT₃ is insensitive to inhibition by cocaine and antidepressant drugs but is inhibited directly by the [glucocorticoid hormone corticosterone](#). Thus, OCT₃ represents a novel, stress hormone-sensitive, monoamine transport mechanism. Incorporating this transporter into current models of [monoaminergic neurotransmission](#) requires information on: A) the [cellular and subcellular localization](#) of the transporter; B) the effects of OCT₃ inhibitors on monoamine clearance; and C) the consequences of decreased OCT₃-mediated transport on physiology and/or behavior. This review summarizes

studies describing the anatomical distribution of OCT₃, its cellular and subcellular localization, its contribution to the regulation of [dopaminergic](#) signaling, and its roles in the regulation of behavior. Together, these and other studies suggest that both Uptake₁ and Uptake₂ transporters play key roles in regulating monoaminergic neurotransmission and the effects of monoamines on behavior.

1. Introduction

[Monoamines](#), including dopamine, [serotonin](#), [epinephrine](#) and [norepinephrine](#), exert powerful modulatory influences on [brain function](#) and behavior via actions mediated by [receptors](#) on neuronal and [glial cells](#). The magnitude of released monoamine signals is determined not only by [diffusion](#), but also by transporter-mediated clearance. Current models of dopamine signaling have suggested that dopamine concentration is primarily regulated by diffusion immediately surrounding release sites, but that transporter-mediated uptake determines the duration and physical spread of released monoamines ([Rice and Cragg, 2008](#)). Thus, uptake processes dictate the extent to which high- and low-affinity monoamine receptors are activated and, thus, the extent to which thousands of surrounding [synapses](#) are influenced. For these reasons, understanding the diversity and complexity of uptake processes is critical for a complete understanding of [monoaminergic neurotransmission](#).

Most studies of monoamine uptake have focused on the high-affinity sodium-dependent transporters which constitute the “Uptake₁” family of monoamine transporters (DAT – [dopamine transporter](#); NET – [norepinephrine transporter](#); and SERT – serotonin [reuptake](#) transporter) and are expressed almost exclusively on the [axon terminals](#) of the monoamine releasing neurons. However, it has long been known that an “Uptake₂” family of low-affinity, high-capacity transporters also contributes to monoamine clearance ([Iversen, 1965](#)). This review focuses on studies examining the localization of one uptake₂ transporter, organic cation transporter 3 (OCT₃), and its roles in the regulation of [dopaminergic](#) neurotransmission and behavior.

2. Catecholamine Uptake₁ and Uptake₂

Early studies of [catecholamine](#) transport in heart tissue revealed the presence of two distinct uptake processes, termed uptake₁ and uptake₂, which differed in [kinetic](#) properties and sensitivity to inhibitors. Uptake₁, a high-affinity ($K_d = 0.27 \mu\text{M}$), low-capacity ($V_{\text{max}} = 1.22 \text{ nmol/min/g tissue}$) transport process, was inhibited by cocaine and [desipramine](#). Uptake₂, a low-affinity ($K_d = 252 \mu\text{M}$), high-capacity ($V_{\text{max}} = 100 \text{ nmol/min/g}$) process, while insensitive to cocaine and desipramine, was inhibited by [normetanephrine](#) and [corticosterone](#) ([Iversen, 1965](#)) ([Iversen and Salt, 1970](#)). Based on its low affinity, uptake₂ was originally believed to contribute to catecholamine clearance only when substrates were present at very high concentrations. However, subsequent studies demonstrated that uptake₂ contributed to catecholamine clearance at all [substrate concentrations](#) ([Lightman and Iversen, 1969](#)).

Uptake₂-like activity has been attributed to at least four distinct transporters. These transporters, including the [organic cation transporters](#) (OCT₁, OCT₂, and OCT₃) and the plasma membrane [monoamine](#) transporter (PMAT), all display high-capacity, bidirectional, sodium-independent transport of monoamines, with each transporter displaying a distinct [substrate specificity](#) profile for monoamines ([Duan and Wang, 2010](#); [Schomig et al., 2006](#)). Although they were all (except for PMAT) originally described in peripheral tissues, all uptake₂ transporters have been detected in brain tissue ([Amphoux et al., 2006](#); [Engel et al., 2004](#)). All are inhibited by corticosterone, although the sensitivity to corticosterone varies depending on the species examined and the [tissue preparation](#) used (reviewed in [Koepsell et al. \(2007\)](#)). Importantly, corticosterone-induced inhibition of OCT-mediated transport is rapid and involves direct interaction of the [steroid](#) with the transporter at specific sites ([Volk et al., 2009](#)). OCT₃ is the most corticosteroid-sensitive, with IC₅₀s in the physiological range for corticosterone ([Gasser et al., 2006](#); [Grundemann et al., 1998](#); [Hill et al., 2011](#)). This property positions OCT₃ as a critical [mediator](#) of stress and [corticosteroid](#) effects on neuronal and glial physiology and behavior

independent of the glucocorticoid receptor (see [Gasser and Lowry \(2018\)](#)), for a review of OCT₃ as a mediator of non-genomic corticosteroid actions).

3. Cellular and subcellular localization of OCT₃

Understanding the roles of OCT₃ in regulating [monoaminergic neurotransmission](#) and in mediating the effects of [corticosterone](#) on [monoamine](#) signaling and behavior requires knowledge of the regional, [cellular and subcellular distribution](#) of the transporter. Immunohistochemical studies with an OCT₃-specific antibody have revealed that the transporter is expressed throughout the rat brain, with at least low levels of expression detected in nearly all brain regions ([Gasser et al., 2009](#)). The transporter is expressed in neurons ([Cui et al., 2009](#); [Graf et al., 2013](#); [Hill and Gasser, 2013](#); [Shang et al., 2003](#); [Vialou et al., 2004](#)), including dopamine neurons ([Mayer et al., 2018](#)), and [glial cells](#), including [astrocytes](#) ([Cui et al., 2009](#); [Gasser et al., 2017](#); [Takeda et al., 2002](#)) and [microglia](#) ([He et al., 2017](#)). It is also expressed in [oligodendrocytes](#) ([Gasser et al., 2009](#)), [ependymal cells](#) ([Gasser et al., 2006, 2009](#)), and vascular endothelial cells in the brain ([Li et al., 2013](#)). The broad expression of this high-capacity monoamine transporter suggests that it plays an essential role in the regulation of extracellular monoamine concentrations in a variety of microenvironments.

The degree to which OCT₃-mediated transport activity determines the activation of monoamine [receptors](#) critically depends on the subcellular localization of the transporter, especially its proximity to monoamine release sites and receptors ([Fig. 1](#)). While there have been no studies directly examining the co-localization of OCT₃ and monoamine release sites or receptors, a recent report described the subcellular localization of the transporter in rat brain using immuno-electron microscopy ([Gasser et al., 2017](#)). This study demonstrated OCT₃ localization to plasma membranes of neuronal [somata](#), as well as to dendritic and axonal profiles. OCT₃ was also densely expressed in plasma membranes of astrocyte processes surrounding axodendritic and axospinous profiles. Positioned at these sites, OCT₃-mediated transport may exert considerable influence over the duration and spread of released monoamines, and thus over the activation of monoamine receptors on both pre- and post-synaptic cells ([Fig. 1](#)).




Fig. 1. Schematic model of the potential roles of OCT₃-mediated transport, and its inhibition by [corticosterone](#), in regulating [monoamine](#) signaling, and highlighting key outstanding questions regarding the localization and actions of OCT₃. [Monoaminergic](#) terminals are depicted adjacent to a cell expressing plasma [membrane receptors](#) for monoamines under conditions of low (A) and high (B) concentrations of corticosterone. OCT₃-mediated, high capacity monoamine transport is hypothesized to play important roles in regulating the duration and physical spread of released monoamines. **A)** The specific roles played by OCT₃ in regulating monoaminergic transmission depend on the answers to key questions regarding 1) the localization of OCT₃ with respect to monoamine release sites; 2) the proximity of OCT₃ to monoamine receptors; and 3) the identity of the OCT₃-expressing cells. **B)** While several studies have demonstrated OCT₃-mediated, corticosterone-sensitive monoamine clearance, key unanswered questions remain, including 4) the effects of corticosterone-induced inhibition on the physical spread and duration of released monoamines; and 5) the activation of low- and high-affinity monoamine receptors in target brain regions.

4. Effects of corticosterone on dopamine clearance: *in vivo* studies

The anatomical studies indicating that OCT₃ is positioned to make important contributions to the clearance of released [monoamines](#) are consistent with *ex vivo* studies which have demonstrated OCT₃-mediated, corticosterone-sensitive uptake of monoamines ([Amphoux et al., 2006](#); [Duan and Wang, 2010](#)). This section summarizes studies in which we examined the effects of DAT inhibition (by cocaine or GRB12909) and OCT₃ inhibition (by corticosterone) on extracellular dopamine concentrations (by microdialysis) and clearance (using fast-scan cyclic voltammetry). These studies were focused on understanding the mechanisms by which stress, through elevation of [glucocorticoid hormones](#), increases the reinstatement of cocaine seeking in rats with a history of cocaine self-administration. All of these studies examined the regulation of dopamine signaling in the [nucleus accumbens](#), a region in which both DAT and OCT₃ are expressed ([Gasser et al., 2009](#)), and an important site of dopamine action in the regulation of motivated behavior. Previous studies by Cui and colleagues provided convincing evidence that OCT₃ plays a role in striatal dopamine clearance. These studies

examined the effects of [methamphetamine](#) and the [neurotoxin1-methyl-4-phenylpyridinium](#) (MPP⁺), two dopamine-releasing agents, on extracellular dopamine levels in the [dorsal striatum](#) of wild-type and OCT₃-deficient mice. Increases in striatal extracellular dopamine induced by both methamphetamine and MPP⁺ were significantly larger, and lasted significantly longer, in OCT₃-deficient mice than in wild-type mice ([Cui et al., 2009](#)).

Studies aimed at examining potential joint roles of OCT₃ and DAT in regulating dopamine signaling tested the effects [corticosterone](#) and cocaine, alone and in combination, on extracellular dopamine concentrations in the rat nucleus accumbens ([Graf et al., 2013](#)). Rats were injected with vehicle or corticosterone (2 mg/kg, ip, a dose that approximates plasma concentrations reached in response to stress), followed by a low dose of cocaine (2.5 mg/kg), during the collection of dialysate samples from the nucleus accumbens. Corticosterone alone had no effect on basal extracellular dopamine concentrations. Surprisingly, low-dose cocaine alone had no effect on extracellular dopamine concentrations when preceded by vehicle injection. However, that same dose of cocaine caused significant increases in extracellular dopamine when it was preceded by an injection of corticosterone ([Graf et al., 2013](#)). These results are consistent with the hypothesis that corticosterone-induced potentiation of low-dose cocaine effects are due to inhibition of OCT₃-mediated DA clearance, but because [microdialysis](#) does not allow direct quantification of dopamine clearance, the results may also be due to corticosterone-induced changes in the release or metabolism of dopamine.

Direct assessment of the effects of corticosterone on DA *clearance*, required the use of *in vivo* fast-scan cyclic [voltammetry](#) (FSCV), an electrochemical technique that measures dopamine concentrations on a sub-second time-scale, allowing detection of changes in [dopamine release](#) and clearance. In studies on anesthetized rats, we examined the effects of corticosterone, in the presence or absence of the DAT inhibitor GBR12909, on the clearance of dopamine released in the nucleus accumbens in response to electrical stimulation of the [ventral tegmental area](#) projection ([Graf et al., 2013](#)). After basal release and uptake parameters were collected, animals received an injection of the DAT inhibitor GBR12909, which significantly decreased the clearance (increased full width at half height (FWHH), apparent K_m, and tau). After the effects of DAT blockade had stabilized, animals received an injection of vehicle or corticosterone (2 mg/kg, ip), and release and clearance parameters were again measured. Injection of corticosterone, but not vehicle, resulted in further decreases in dopamine clearance (further increases in FWHH, apparent K_m, and tau), revealing for the first time in an *in vivo* study, the presence of corticosterone-sensitive, DAT-independent clearance of dopamine *in vivo* ([Graf et al., 2013](#)).

Subsequent studies used FSCV to examine the effects of corticosterone on dopamine clearance in [awake](#) and behaving animals. In these studies, animals were treated with corticosterone (2 mg/kg, ip) or low-dose cocaine (2.5 mg/kg, ip), alone or in combination, and the amplitude and duration of naturally-occurring dopamine transients in the nucleus accumbens were measured. Surprisingly, administration of corticosterone alone, but not low-dose cocaine alone, significantly increased the duration and magnitude of spontaneous dopamine transients. Low-dose cocaine, while it had no effect on transient amplitude or duration alone, did induce robust increases in these measures when it was administered after corticosterone ([Wheeler et al., 2017](#)). These results indicate that, even in a DAT-rich region like the nucleus accumbens, corticosterone-induced decreases in DA clearance can be observed in the absence of DAT blockade, and that uptake₁ (DAT-mediated) and uptake₂ (likely OCT₃-mediated) transport work in concert to shape dopamine signals *in vivo*. The relative contributions of uptake₁ and uptake₂ processes to regulating specific monoamine signaling will likely vary regionally, depending on both the distributions of the transporters and the patterns of monoamine release.

5. Corticosterone and the regulation of cocaine-seeking behavior: a role for OCT₃

The anatomical and [neurochemical](#) studies described above suggest that OCT₃-mediated clearance may contribute significantly to the regulation of dopamine-dependent [physiological processes](#), such as [spike timing-dependent plasticity](#) (in cortical regions) and dopamine-dependent behavioral processes, including reward- and motivation-related behaviors. As it is inhibited by physiological concentrations of [corticosterone](#), it represents a mechanism by which stress, via elevating [glucocorticoids](#), may regulate [brain function](#) and behavior. Much work remains to clarify the contribution of OCT₃ and other uptake₂transporters in physiological and behavioral processes. The remainder of this review focuses on work we have done to examine a potential role of OCT₃ in mediating glucocorticoid-induced alterations in cocaine-seeking behavior in rats.

A series of behavioral studies examined the interaction of stress-levels of corticosterone with subthreshold doses of cocaine in rodent models of addiction ([Graf et al., 2013](#); [McReynolds et al., 2017](#)). All studies involved training of rats or mice to associate lever pressing (rat self-administration) or a specific chamber (mouse [conditioned place-preference](#) (CPP)) with the administration of cocaine. Acquisition of the task is followed by a maintenance phase, in which drugself-administration is stably expressed, and then by extinction training, in which lever pressing or entry into the cocaine-paired chamber results in the administration of saline instead of cocaine. This leads to the extinction of the cocaine-conditioned behavior. Reinstatement of cocaine-seeking behavior (pressing the lever in the absence of a cocaine reward (rat self-administration studies), or entry into the previously cocaine-paired chamber in the absence of drug reinforcement (mouse CPP studies)) in response to stress, low-dose cocaine, or corticosterone treatment is interpreted as [drug-seeking behavior](#).

The ability of corticosterone to influence reinstatement of drug-seeking behavior was tested in rats which had been trained to self-administer cocaine under short-access conditions (2 h daily access to the drug) ([Graf et al., 2013](#); [McReynolds et al., 2017](#)). Rats trained under short-access conditions, compared to those trained under long-access conditions, are resistant to stress- or cocaine-induced reinstatement of drug seeking behavior. Specifically, these animals do not resume lever pressing during reinstatement tests after either an injection of a low dose of cocaine (2.5 mg/kg), or exposure to 15 min of intermittent electric [footshock stress](#). While neither of these two stimuli alone induces significant reinstatement of drug-seeking behavior, combination of the two (low dose cocaine preceded, 40 min earlier, by electric footshock) does ([Graf et al., 2013](#); [McReynolds et al., 2017](#)). The effects of stress could be mimicked either by [intraperitoneal injection](#) of corticosterone at a dose that reproduces stress levels of the hormone (a treatment that did not by itself lead to reinstatement), or by bilateral injection of either corticosterone or the OCT₃ inhibitor [normetanephrine](#) into the [nucleus accumbens](#). The ability of corticosterone to potentiate low-dose cocaine-induced reinstatement was unaffected by pretreatment with RU-38486, an inhibitor of the glucocorticoid receptor, indicating that the [corticosteroid](#) effect was not mediated by the intracellular glucocorticoid receptor. The potentiating effect *was* blocked by intra-nucleus accumbens injection of [fluphenazine](#), a DA [receptor antagonist](#) ([Graf et al., 2013](#); [McReynolds et al., 2017](#)). Together, these behavioral studies indicate that corticosterone-induced potentiation of drug seeking is mediated by a GR-independent mechanism involving local striatal dopamine signaling. In combination with the anatomical and neurochemical studies described above, these data are consistent with the hypothesis that corticosterone-induced potentiation of reinstatement involves inhibition of OCT₃-mediated clearance. However, due to the lack of mono-specific inhibitors of OCT₃, these findings did not rule out the involvement of other cellular mechanisms.

To more definitively demonstrate a role for OCT₃ inhibition in corticosterone-induced potentiation of cocaine-primed reinstatement, we examined the reinstatement of cocaine conditioned place preference in wild type mice, and in transgenic OCT₃-deficient mice that express a truncated form of OCT₃, and lack OCT₃-mediated

transport activity ([Zwart et al., 2001](#)). Both wild-type and OCT₃ deficient mice acquired CPP to a [high dose](#) of cocaine (15 mg/kg) and extinguished drug-seeking behavior in a similar time course. Reinstatement of CPP was measured in response to a subthreshold dose of cocaine (0.93 mg/kg), which did not lead to significant reinstatement in wild-type mice. In wild-type mice, injection of either corticosterone or normetanephrine potentiated low-dose cocaine-induced reinstatement of CPP, but neither OCT₃ inhibitor potentiated reinstatement in OCT₃-deficient mice ([McReynolds et al., 2017](#)). Together, the rodent reinstatement studies coupled with the neurochemical measures indicate that the ability of stress and corticosterone to influence cocaine-seeking behavior is mediated, at least in part, by corticosterone-induced inhibition of dopamine clearance in the nucleus accumbens.

The anatomical, neurochemical and behavioral studies described here suggest that uptake₁ and uptake₂ processes work together in a region- and context-specific manner to regulate the amplitude, duration and physical spread of dopamine signals and, thus, to determine the neuromodulatory influence of released dopamine. Although the studies described in this review focused on the role of OCT₃ in regulating [dopaminergic](#) signaling, similar roles for OCT₃ (and other uptake₂transporters) in the regulation of noradrenergic, [serotonergic](#) and [histaminergic neurotransmission](#) likely exist. Indeed, a significant body of research has demonstrated roles for OCT₃ and PMAT in serotonergic transmission ([Baganz et al., 2008, 2010](#); [Dahlin et al., 2007](#)). Similarly, this review focused on our studies examining OCT₃-mediated dopamine transport as it relates to the neurochemical and behavioral effects of cocaine. There is a growing body of work examining roles for OCT₃-mediated dopamine transport in the actions of other [psychostimulant](#) drugs, including [amphetamine](#) ([Mayer et al., 2018](#); [Vialou et al., 2008](#)) and [methamphetamine](#) ([Cui et al., 2009](#); [Kitaichi et al., 2003](#); [Nakayama et al., 2007](#)). Clearly, many questions remain to be answered about the roles played by OCT₃ and the other uptake₂ transporters in regulating [monoamine](#) signaling throughout the brain ([Gasser and Daws, 2017](#)).

Acknowledgements

Supported by grant National Institute on Drug Abuse ([DA032895](#)) to PJG.

References

- [Amphoux et al., 2006](#) A. Amphoux, V. Vialou, E. Drescher, M. Bruss, C.M. La Cour, C. Rochat, M.J. Millan, B. Giros, H. Bonisch, S. Gautron **Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain** *Neuropharmacology*, 50 (2006), pp. 941-952
- [Baganz et al., 2010](#) N. Baganz, R. Horton, K. Martin, A. Holmes, L.C. Daws **Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun** *J. Neurosci.*, 30 (2010), pp. 15185-15195
- [Baganz et al., 2008](#) N.L. Baganz, R.E. Horton, A.S. Calderon, W.A. Owens, J.L. Munn, L.T. Watts, N. Koldzic-Zivanovic, N.A. Jeske, W. Koek, G.M. Toney, L.C. Daws **Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice** *Proc. Natl. Acad. Sci. U. S. A.*, 105 (2008), pp. 18976-18981
- [Cui et al., 2009](#) M. Cui, R. Aras, W.V. Christian, P.M. Rappold, M. Hatwar, J. Panza, V. Jackson-Lewis, J.A. Javitch, N. Ballatori, S. Przedborski, K. Tieu **The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway** *Proc. Natl. Acad. Sci. U. S. A.*, 106 (2009), pp. 8043-8048
- [Dahlin et al., 2007](#) Dahlin, L. Xia, W. Kong, R. Hevner, J. Wang **Expression and immunolocalization of the plasma membrane monoamine transporter in the brain** *Neuroscience*, 146 (2007), pp. 1193-1211

- [Duan and Wang, 2010](#) H. Duan, J. Wang **Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3** *J. Pharmacol. Exp. Therapeut.*, 335 (2010), pp. 743-754
- [Engel et al., 2004](#) K. Engel, M. Zhou, J. Wang **Identification and characterization of a novel monoamine transporter in the human brain** *J. Biol. Chem.*, 279 (2004), pp. 50042-50049
- [Gasser and Daws, 2017](#) P.J. Gasser, L.C. Daws **Extending the family: roles for uptake2 transporters in regulation of monoaminergic signaling** *J. Chem. Neuroanat.*, 83–84 (2017), pp. 107-108
- [Gasser et al., 2017](#) P.J. Gasser, M.M. Hurley, J. Chan, V.M. Pickel **Organic cation transporter 3 (OCT₃) is localized to intracellular and surface membranes in select glial and neuronal cells within the basolateral amygdaloid complex of both rats and mice** *Brain Struct. Funct.*, 222 (2017), pp. 1913-1928
- [Gasser and Lowry, 2018](#) P.J. Gasser, C.A. Lowry **Organic cation transporter 3: a cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior** *Horm. Behav.* (2018), [10.1016/j.yhbeh.2018.05.003](#)
- [Gasser et al., 2006](#) P.J. Gasser, C.A. Lowry, M. Orchinik **Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission** *J. Neurosci.*, 26 (2006), pp. 8758-8766
- [Gasser et al., 2009](#) P.J. Gasser, M. Orchinik, I. Raju, C.A. Lowry **Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain** *J. Comp. Neurol.*, 512 (2009), pp. 529-555
- [Graf et al., 2013](#)
E.N. Graf, R.A. Wheeler, D.A. Baker, A.L. Ebben, J.E. Hill, J.R. McReynolds, M.A. Robble, O. Vranjkovic, D.S. Wheeler, J.R. Mantsch, P.J. Gasser **Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking** *J. Neurosci.*, 33 (2013), pp. 11800-11810
- [Grundemann et al., 1998](#) D. Grundemann, B. Schechinger, G.A. Rappold, E. Schomig **Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter** *Nat. Neurosci.*, 1 (1998), pp. 349-351
- [He et al., 2017](#) Q. He, Q. Wang, C. Yuan, Y. Wang **Downregulation of miR-7116-5p in microglia by MPP+ sensitizes TNF-alpha production to induce dopaminergic neuron damage** *Glia*, 65 (2017), pp. 1251-1263
- [Hill and Gasser, 2013](#) J.E. Hill, P.J. Gasser **Organic cation transporter 3 is densely expressed in the intercalated cell groups of the amygdala: anatomical evidence for a stress hormone-sensitive dopamine clearance system** *J. Chem. Neuroanat.*, 52 (2013), pp. 36-43
- [Hill et al., 2011](#) J.E. Hill, K. Makky, L. Shrestha, C.J. Hillard, P.J. Gasser **Natural and synthetic corticosteroids inhibit uptake 2-mediated transport in CNS neurons** *Physiol. Behav.*, 104 (2011), pp. 306-311
- [Iversen, 1965](#) L.L. Iversen **The uptake of adrenaline by the rat isolated heart** *Br. J. Pharmacol.*, 24 (1965), pp. 387-394
- [Iversen and Salt, 1970](#) L.L. Iversen, P.J. Salt **Inhibition of catecholamine Uptake-2 by steroids in the isolated rat heart** *Br. J. Pharmacol.*, 40 (1970), pp. 528-530
- [Kitaichi et al., 2003](#) K. Kitaichi, Y. Morishita, Y. Doi, J. Ueyama, M. Matsushima, Y.L. Zhao, K. Takagi, T. Hasegawa **Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats** *Eur. J. Pharmacol.*, 464 (2003), pp. 39-48
- [Koepsell et al., 2007](#) H. Koepsell, K. Lips, C. Volk **Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications** *Pharm. Res. (N. Y.)*, 24 (7) (2007), pp. 1227-1251
- [Li et al., 2013](#) R.W. Li, C. Yang, Y.W. Kwan, S.W. Chan, S.M. Lee, G.P. Leung **Involvement of organic cation transporter-3 and plasma membrane monoamine transporter in serotonin uptake in human brain vascular smooth muscle cells** *Front. Pharmacol.*, 4 (2013), p. 14
- [Lightman and Iversen, 1969](#) S.L. Lightman, L.L. Iversen **The role of uptake₂ in the extraneuronal metabolism of catecholamines in the isolated rat heart** *Br. J. Pharmacol.*, 37 (1969), pp. 638-649

[Mayer et al., 2018](#)

F.P. Mayer, D. Schmid, W.A. Owens, G.G. Gould, M. Apuschkin, O. Kudlacek, I. Salzer, S. Boehm, P. Chiba, P.H. Williams, H.H. Wu, U. Gether, W. Koek, L.C. Daws, H.H. Sitte **An unsuspected role for organic cation transporter 3 in the actions of amphetamine** *Neuropsychopharmacology* (2018), [10.1038/s41386-018-0053-5](#)

[McReynolds et al., 2017](#)

J.R. McReynolds, A. Taylor, O. Vranjkovic, T. Ambrosius, O. Derricks, B. Nino, B. Kurtoglu, R.A. Wheeler, D.A. Baker, P.J. Gasser, J.R. Mantsch **Corticosterone potentiation of cocaine-induced reinstatement of conditioned place preference in mice is mediated by blockade of the organic cation transporter 3** *Neuropsychopharmacology*, 42 (2017), pp. 757-765

[Nakayama et al., 2007](#)

H. Nakayama, K. Kitaichi, Y. Ito, K. Hashimoto, K. Takagi, T. Yokoi, K. Takagi, N. Ozaki, T. Yamamoto, T. Hasegawa **The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats** *Brain Res.*, 1184 (2007), pp. 260-269

[Rice and Cragg, 2008](#) M.E. Rice, S.J. Cragg **Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway** *Brain Res. Rev.*, 58 (2) (2008), pp. 303-313

[Schomig et al., 2006](#) E. Schomig, A. Lazar, D. Grundemann **Extraneuronal monoamine transporter and organic cation transporters 1 and 2: a review of transport efficiency** *Handb. Exp. Pharmacol.*, 175 (2006), pp. 151-180

[Shang et al., 2003](#) T. Shang, A.V. Uihlein, J. Van Asten, B. Kalyanaraman, C.J. Hillard **1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3** *J. Neurochem.*, 85 (2003), pp. 358-367

[Takeda et al., 2002](#) H. Takeda, M. Inazu, T. Matsumiya **Astroglial dopamine transport is mediated by norepinephrine transporter** *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 366 (2002), pp. 620-623

[Vialou et al., 2004](#) V. Vialou, A. Amphoux, R. Zwart, B. Giros, S. Gautron **Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation** *J. Neurosci.*, 24 (2004), pp. 2846-2851

[Vialou et al., 2008](#) V. Vialou, L. Balasse, J. Callebert, J.M. Launay, B. Giros, S. Gautron **Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice** *J. Neurochem.*, 106 (2008), pp. 1471-1482

[Volk et al., 2009](#) C. Volk, V. Gorboulev, A. Kotzsch, T.D. Mueller, H. Koepsell **Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone** *Mol. Pharmacol.*, 76 (2) (2009), pp. 275-289

[Wheeler et al., 2017](#)

D.S. Wheeler, A.L. Ebben, B. Kurtoglu, M.E. Lovell, A.T. Bohn, I.A. Jasek, D.A. Baker, J.R. Mantsch, P.J. Gasser, R.A. Wheeler **Corticosterone regulates both naturally occurring and cocaine-induced dopamine signaling by selectively decreasing dopamine uptake** *Eur. J. Neurosci.*, 46 (2017), pp. 2638-2646

[Zwart et al., 2001](#) R. Zwart, S. Verhaagh, M. Buitelaar, C. Popp-Snijders, D.P. Barlow **Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice** *Mol. Cell Biol.*, 21 (2001), pp. 4188-4196